News Releases

More events are coming soon.
DateTitle 
10/11/18
First SYK inhibitor for the treatment of adult chronic ITP SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq: RIGL) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for fostamatinib
09/27/18
SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it will host an investor and analyst day event on Thursday, October 4, 2018 from 12:00pm to 2:30pm Eastern Time in New York City .
09/24/18
SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled to present a company overview at the Cantor Global Healthcare Conference in New York City
08/29/18

SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's executive vice president and chief financial officer, is scheduled to present a company overview at the 20th Annual Rodman & Renshaw Global

08/08/18

$1.8 Million in Net Product Sales for TAVALISSE™ (fostamatinib disodium hexahydrate) Conference Call and Webcast Today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 8, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the second

08/01/18

SOUTH SAN FRANCISCO, Calif. , Aug. 1, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it will report its second quarter 2018 financial results after market close on Wednesday, August 8 , 2018. Rigel senior management will follow the announcement with a live

06/26/18
SOUTH SAN FRANCISCO, Calif. , June 26, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq: RIGL) today announced that it has initiated a Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects.
06/20/18
SOUTH SAN FRANCISCO, Calif. , June 20, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dr. Anne-Marie Duliege, Chief Medical Officer, will be presenting two posters on fostamatinib at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting in San
06/12/18

SOUTH SAN FRANCISCO, Calif. , June 12, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will be presenting an oral presentation on the Phase 2 Stage 1 interim results for fostamatinib in patients with warm antibody hemolytic anemia (AIHA) at the 23 rd Congress

05/31/18

SOUTH SAN FRANCISCO, Calif. , May 31, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Global Healthcare Conference in New York City

05/30/18

SOUTH SAN FRANCISCO, Calif. , May 30, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq:RIGL) today announced that it has appointed Dean Schorno , CPA as Executive Vice President and Chief Financial Officer (CFO). Formerly the CFO and Head of Operations at 23andMe, Inc. , Mr.

05/29/18
Launches RIGEL ONECARE™ to Support Patients and Providers SOUTH SAN FRANCISCO, Calif. , May 29, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that TAVALISSE™ (fostamatinib disodium hexahydrate) is available by prescription for the treatment of thrombocytopenia in
05/01/18

Rigel Expected to Launch TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S. in late May 2018 Conference Call and Webcast Today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the

04/30/18

SOUTH SAN FRANCISCO, Calif. , April 30, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the American Journal of Hematology has published positive results from the Fostamatinib in Thrombocytopenia (FIT) Phase 3 clinical program of TAVALISSE™ (fostamatinib

04/24/18

SOUTH SAN FRANCISCO, Calif. , April 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2018 financial results after market close on Tuesday, May 1 , 2018.  Rigel senior management will follow the announcement with a live

04/19/18
SOUTH SAN FRANCISCO, Calif. , April 19, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of $3.90 per share to the public.  The gross
04/18/18
SOUTH SAN FRANCISCO, Calif. , April 18, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to
04/17/18
TAVALISSE Offers First-in-Class Treatment with Unique Mechanism of Action U.S. Commercial Launch Expected in Late May 2018 Conference Call and Webcast to be Held Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , April 17, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq:RIGL)
04/12/18
SOUTH SAN FRANCISCO, Calif. , April 12, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq: RIGL), reported that due to an error by the external host of its investor relations website, inaccurate information was displayed regarding the U.S. Food and Drug Administration's ( FDA ) review of
04/03/18
Company to host a conference call today at 8:00AM EDT to Discuss the Study Results SOUTH SAN FRANCISCO, Calif. , April 3, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq:RIGL), today announced topline data from its proof-of-concept Phase 2 study of fostamatinib in patients with IgA
03/06/18
Conference Call and Webcast Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 6, 2018 /PRNewswire/ -- Rigel Pharmaceuticals , Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year end 2017. Recent Achievements The U.S.
03/01/18
SOUTH SAN FRANCISCO, Calif. , March 1, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib data from its FIT Phase 3 extension study (FIT3) in patients with chronic immune thrombocytopenia (ITP) and preliminary data from its SOAR Phase 2 clinical
02/27/18
SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2017 financial results after market close on Tuesday, March 6 , 2018.  Rigel senior management will follow the announcement with
01/04/18
SOUTH SAN FRANCISCO, Calif. , Jan. 4, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present an update on its product pipeline and a financial overview at the upcoming 36 th  Annual J.P.